| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00460473 Details | 2015-07-24 Interventional | 3 | 52 | Dexmedetomidine Delirium | The incidence of post-operative delirium observed from interim blinded data was significantly
lower than the current literature in this population. - | |||
| NCT02137564 Details | 2015-07-23 Interventional | 2 | 0 | Gamma Secretase… Nirogacestat Sarcoma Sarcoma, Kaposi AIDS-related Ka… HIV Infection Recurrent Kapos… | Drug supply unavailable - | |||
| NCT00788424 Details | 2015-07-23 Interventional | 2 | 0 | Ammonium trichl… Psoriasis Mild to Moderat… | Sponsor's considerations - | |||
| NCT01796522 Details | 2015-07-22 Interventional | 3 | 0 | Nifedipine Progesterone Premature Birth Preterm Deliver… | have been published new studies that it showed the ineffectiveness of the treatments proposed
in this study. - | |||
| NCT01444118 Details | 2015-07-22 Interventional | 3 | - | Cyclophosphamid… Monatide (IMS 3… Vaccines Carcinoma, Non-… | The early termination is not related to safety/toxicity but to initiate new Phase III with
biomarker to enrich population & to further strengthen OS benefit - | |||
| NCT01517776 2009-011898-33 Details | 2015-07-21 Interventional | 2 | 28 | Temozolomide Diffuse Intrins… Glioma Gliomas | due to an altered benefit/risk assessment. - | |||
| NCT00871273 Details | 2015-07-21 Interventional | 4 | 13 | Capecitabine Adenocarcinoma Adenocarcinoma … | 1. Slow recruitment; 2. Change to clinical environment reducing the pool of potentially
eligible patients; 3. Availability of data from another similar study - | |||
| NCT02397395 2014-004250-34 Details | 2015-07-17 Interventional | 2 | 0 | Simeprevir Hepatitis C Hepatitis C, Ch… Kidney Diseases Kidney Failure,… Renal Insuffici… End-stage Renal… Renal Impairmen… | Trial has been cancelled due to availability of new therapeutic options for patient population - | |||
| NCT01227434 Details | 2015-07-17 Interventional | 2 | 23 | Palbociclib Astrocytoma Glioblastoma Gliosarcoma Anaplastic Astr… | - - | |||
| NCT01642433 Details | 2015-07-16 Interventional | 2 | 1 | Prazosin Tobacco Use Dis… Nicotine Depend… | - - | |||
| NCT01848652 Details | 2015-07-14 Interventional | 2 | 5 | Doxorubicin Lymphoma Lymphoma, B-Cel… Cerebral Lympho… | The laboratory's partner on this study decides to terminate the contract with the CHRU Brest,
because of the difficulty of the recruitment. - | |||
| NCT01282151 Details | 2015-07-14 Interventional | 3 | 148 | Cisplatin Docetaxel Pemetrexed Carcinoma, Non-… Carcinoma, Non … | Difficulty in recruitment due to approval of maintenance pemetrexed treatment - | |||
| NCT00779285 2004-001177-25 Details | 2015-07-14 Interventional | 4 | 1 | Doxorubicin Liposomal doxor… Breast Neoplasm… Breast Neoplasm | - - | |||
| NCT01928160 Details | 2015-07-13 Interventional | 2 | 0 | Carboplatin Erlotinib Hydro… Pemetrexed Carcinoma, Non-… Lung Neoplasms Recurrent Non-s… Stage IV Non-sm… | study not accruing - | |||
| NCT01443923 Details | 2015-07-13 Interventional | 4 | 4 | Interferon alph… Interferon-alph… Interferons Peginterferon a… Ribavirin Hepatitis Hepatitis A HIV/AIDS | Unable to complete enrollment due to newly approved treatment options. - | |||
| NCT01039545 Details | 2015-07-09 Interventional | 4 | 253 | Diclofenac Norfloxacin Communicable Di… Infections Urinary Tract I… | New power calculation (reduction of necessary patient number) - | |||
| NCT00905398 Details | 2015-07-09 Interventional | 1/2 | 8 | Nilotinib Leukemia Leukemia, Lymph… Precursor B-Cel… Precursor Cell … Acute Lymphobla… | The study was terminated due to excessive toxicity and low compliance to the protocol scheme. - | |||
| NCT01843309 Details | 2015-07-07 Interventional | 4 | 36 | Spironolactone Congenital Abno… Patients With F… | Not possible to complete the sample within the estimated time by the use of new antifungals - | |||
| NCT00486720 Details | 2015-07-03 Interventional | 2 | 22 | Vorinostat Bone Marrow Dis… Hematologic Dis… Myelodysplastic… Preleukemia Syndrome Blood Disease Bone Marrow Dis… | - This trial was terminated because the pre-specified futility criterion was met. | |||
| NCT00473889 Details | 2015-07-03 Interventional | 2/3 | 253 | Carboplatin Paclitaxel Vorinostat Carcinoma, Non-… Lung Neoplasms Stage IIIB or I… | The study was terminated based on the recommendation by the DSMB following a pre-planned
protocol interim analysis because the endpoint was not achieved. The study was stopped following a pre-planned interim analysis because the goal for this study to continue was not met, based on 100 events, a reduction in the hazard ratio for progression-free survival by > 23% with a one-sided p-value < 0.1 |